Lixte Biotechnology Holdings, Inc. (LIXT)
| Market Cap | 42.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.08M |
| Shares Out | 11.62M |
| EPS (ttm) | -1.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,798 |
| Open | 3.685 |
| Previous Close | 3.800 |
| Day's Range | 3.410 - 3.685 |
| 52-Week Range | 0.640 - 6.260 |
| Beta | 0.95 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2026 |
About LIXT
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcin... [Read more]
Financial Performance
Financial StatementsNews
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
-Trial Combines LIXTE's LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options-
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advan...
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advanc...
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La...
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-c...
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc....
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic a...
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though, o...
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers
BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / Oncology has spent decades chasing the next magic bullet. The twist is that the next breakthrough may not be a bullet at all.
LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 202...
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a fir...
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnol...
LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)
BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spot...
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)
BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NAS...
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it...
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
Unlocking a New Era in Cancer Treatment Denver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market n...
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW)...
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
LIXTE Biotechnology (Nasdaq: LIXT) advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited tre
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biot...
LIXTE Biotechnology Holdings Provides Corporate Update
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Com...
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information o...
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotec...
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
LIXTE's (Nasdaq:LIXT) BoD approved a bold new treasury policy to diversify its corporate reserves into cryptocurrency, including $BTC & potentially others
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced tha...